Global Cough Hypersensitivity Syndrome Market is valued approximately USD XX million in 2021 and is anticipated to grow with a healthy growth rate of more than XX % over the forecast period 2022-2028. Cough hypersensitivity syndrome (CHS) is a clinical syndrome which causes troublesome coughing. Cough hypersensitivity syndrome triggers due to asthma, postnasal drip, reflux disease, and allergic factors among others. Increasing incidences of chronic respiratory diseases and growing healthcare sector in emerging economies as well as rising trend towards sedentary lifestyle are key drivers for growth of Cough Hypersensitivity Syndrome Market. For instance, according to World Health Organization (WHO)- Chronic Obstructive Pulmonary Disease (COPD) is the third leading cause of death globally. During 2019, globally 3.23 million people succumbs to COPD. Furthermore, as per The Office of Disease Prevention and Health Promotion (ODPHP) - As of 2020, in USA around 25 million people have asthma and around 14.8 million adults have been diagnosed with COPD. Moreover, annual health care expenditures for asthma disease were estimated at USD 20.7 billion. Also, surging geriatric population and increasing number of clinical trials are anticipated to act as a catalyzing factor for the market demand during the forecast period. However, high treatment cost of Cough Hypersensitivity Syndrome impedes the growth of the market over the forecast period of 2022-2028.
The key regions considered for the global Cough Hypersensitivity Syndrome Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America is the leading region across the world in terms of market share owing to the growing prevalence of respiratory disorders and surging healthcare expenditure as well as presence of leading market players in the region. Whereas, North America is anticipated to exhibit a significant growth rate over the forecast period 2022-2028. Factors such as rising geriatric population and increasing investment towards healthcare infrastructure development in the region, would create lucrative growth prospects for the Cough Hypersensitivity Syndrome Market across the Asia Pacific region.
Major market players included in this report are:
Akorn, Incorporated (US)
Pfizer Inc. (U.S.)
GlaxoSmithKline plc (U.K.)
Novartis AG (Switzerland)
Mylan N.V. (U.S.)
Teva Pharmaceutical Industries Ltd.(Israel)
Sanofi (France)
Boehringer Ingelheim International GmbH. (Germany)
AstraZeneca (U.K.)
Johnson & Johnson Private Limited (U.S.)
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Drug Class
Inhales Corticosteroids
Antitussive Agents
Short-acting Beta-2 Agonists
Anticholinergics
Proton Pump Inhibitors
Antihistamines
Others
By Route of Administration
Oral
Inhalation
Others
By End-Users
Hospitals
Specialty Clinics
Homecare
Others
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Others
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World
Furthermore, years considered for the study are as follows:
Historical year - 2018, 2019, 2020
Base year - 2021
Forecast period - 2022 to 2028
Target Audience of the Global Cough Hypersensitivity Syndrome Market in Market Study:
Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors
Table of Contents
Chapter 1. Executive Summary
- 1.1. Market Snapshot
- 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2028 (USD Million)
- 1.2.1. Global Cough Hypersensitivity Syndrome Market, by Region, 2020-2028 (USD Million)
- 1.2.2. Global Cough Hypersensitivity Syndrome Market, by Drug Class, 2020-2028 (USD Million)
- 1.2.3. Global Cough Hypersensitivity Syndrome Market, by Route of Administration, 2020-2028 (USD Million)
- 1.2.4. Global Cough Hypersensitivity Syndrome Market, by End Users, 2020-2028 (USD Million)
- 1.2.5. Global Cough Hypersensitivity Syndrome Market, by Distribution Channel, 2020-2028 (USD Million)
- 1.3. Key Trends
- 1.4. Estimation Methodology
- 1.5. Research Assumption
Chapter 2. Global Cough Hypersensitivity Syndrome Market Definition and Scope
- 2.1. Objective of the Study
- 2.2. Market Definition & Scope
- 2.2.1. Scope of the Study
- 2.2.2. Industry Evolution
- 2.3. Years Considered for the Study
- 2.4. Currency Conversion Rates
Chapter 3. Global Cough Hypersensitivity Syndrome Market Dynamics
- 3.1. Cough Hypersensitivity Syndrome Market Impact Analysis (2020-2028)
- 3.1.1. Market Drivers
- 3.1.1.1. Increasing incidences of chronic respiratory diseases.
- 3.1.1.2. Growing healthcare sector in emerging economies.
- 3.1.1.3. Rising trend towards sedentary lifestyle.
- 3.1.2. Market Challenges
- 3.1.2.1. High treatment cost of Cough Hypersensitivity Syndrome.
- 3.1.3. Market Opportunities
- 3.1.3.1. Surging geriatric population
- 3.1.3.2. Increasing number of clinical trials.
Chapter 4. Global Cough Hypersensitivity Syndrome Market Industry Analysis
- 4.1. Porter's 5 Force Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's 5 Force Model (2018-2028)
- 4.2. PEST Analysis
- 4.2.1. Political
- 4.2.2. Economical
- 4.2.3. Social
- 4.2.4. Technological
- 4.3. Investment Adoption Model
- 4.4. Analyst Recommendation & Conclusion
- 4.5. Top investment opportunity
- 4.6. Top winning strategies
Chapter 5. Risk Assessment: COVID-19 Impact
- 5.1.1. Assessment of the overall impact of COVID-19 on the industry
- 5.1.2. Pre COVID-19 and post COVID-19 Market scenario
Chapter 6. Global Cough Hypersensitivity Syndrome Market, by Drug Class
- 6.1. Market Snapshot
- 6.2. Global Cough Hypersensitivity Syndrome Market by Drug Class, Performance - Potential Analysis
- 6.3. Global Cough Hypersensitivity Syndrome Market Estimates & Forecasts by Drug Class 2018-2028 (USD Million)
- 6.4. Cough Hypersensitivity Syndrome Market, Sub Segment Analysis
- 6.4.1. Inhales Corticosteroids
- 6.4.2. Antitussive Agents
- 6.4.3. Short-acting Beta-2 Agonists
- 6.4.4. Anticholinergics
- 6.4.5. Proton Pump Inhibitors
- 6.4.6. Antihistamines
- 6.4.7. Others
Chapter 7. Global Cough Hypersensitivity Syndrome Market, by Route of Administration
- 7.1. Market Snapshot
- 7.2. Global Cough Hypersensitivity Syndrome Market by Route of Administration, Performance - Potential Analysis
- 7.3. Global Cough Hypersensitivity Syndrome Market Estimates & Forecasts by Route of Administration 2018-2028 (USD Million)
- 7.4. Cough Hypersensitivity Syndrome Market, Sub Segment Analysis
- 7.4.1. Oral
- 7.4.2. Inhalation
- 7.4.3. Others
Chapter 8. Global Cough Hypersensitivity Syndrome Market, by End Users
- 8.1. Market Snapshot
- 8.2. Global Cough Hypersensitivity Syndrome Market by End Users, Performance - Potential Analysis
- 8.3. Global Cough Hypersensitivity Syndrome Market Estimates & Forecasts by End Users 2018-2028 (USD Million)
- 8.4. Cough Hypersensitivity Syndrome Market, Sub Segment Analysis
- 8.4.1. Hospitals
- 8.4.2. Specialty Clinics
- 8.4.3. Homecare
- 8.4.4. Others
Chapter 9. Global Cough Hypersensitivity Syndrome Market, by Distribution Channel
- 9.1. Market Snapshot
- 9.2. Global Cough Hypersensitivity Syndrome Market by Distribution Channel, Performance - Potential Analysis
- 9.3. Global Cough Hypersensitivity Syndrome Market Estimates & Forecasts by Distribution Channel 2018-2028 (USD Million)
- 9.4. Cough Hypersensitivity Syndrome Market, Sub Segment Analysis
- 9.4.1. Hospital Pharmacy
- 9.4.2. Retail Pharmacy
- 9.4.3. Online Pharmacy
- 9.4.4. Others
Chapter 10. Global Cough Hypersensitivity Syndrome Market, Regional Analysis
- 10.1. Cough Hypersensitivity Syndrome Market, Regional Market Snapshot
- 10.2. North America Cough Hypersensitivity Syndrome Market
- 10.2.1. U.S. Cough Hypersensitivity Syndrome Market
- 10.2.1.1. Drug Class estimates & forecasts, 2018-2028
- 10.2.1.2. Route of Administration estimates & forecasts, 2018-2028
- 10.2.1.3. End Users estimates & forecasts, 2018-2028
- 10.2.1.4. Distribution Channel estimates & forecasts, 2018-2028
- 10.2.2. Canada Cough Hypersensitivity Syndrome Market
- 10.3. Europe Cough Hypersensitivity Syndrome Market Snapshot
- 10.3.1. U.K. Cough Hypersensitivity Syndrome Market
- 10.3.2. Germany Cough Hypersensitivity Syndrome Market
- 10.3.3. France Cough Hypersensitivity Syndrome Market
- 10.3.4. Spain Cough Hypersensitivity Syndrome Market
- 10.3.5. Italy Cough Hypersensitivity Syndrome Market
- 10.3.6. Rest of Europe Cough Hypersensitivity Syndrome Market
- 10.4. Asia-Pacific Cough Hypersensitivity Syndrome Market Snapshot
- 10.4.1. China Cough Hypersensitivity Syndrome Market
- 10.4.2. India Cough Hypersensitivity Syndrome Market
- 10.4.3. Japan Cough Hypersensitivity Syndrome Market
- 10.4.4. Australia Cough Hypersensitivity Syndrome Market
- 10.4.5. South Korea Cough Hypersensitivity Syndrome Market
- 10.4.6. Rest of Asia Pacific Cough Hypersensitivity Syndrome Market
- 10.5. Latin America Cough Hypersensitivity Syndrome Market Snapshot
- 10.5.1. Brazil Cough Hypersensitivity Syndrome Market
- 10.5.2. Mexico Cough Hypersensitivity Syndrome Market
- 10.6. Rest of The World Cough Hypersensitivity Syndrome Market
Chapter 11. Competitive Intelligence
- 11.1. Top Market Strategies
- 11.2. Company Profiles
- 11.2.1. Akorn Incorporated (USA)
- 11.2.1.1. Key Information
- 11.2.1.2. Overview
- 11.2.1.3. Financial (Subject to Data Availability)
- 11.2.1.4. Product Summary
- 11.2.1.5. Recent Developments
- 11.2.2. Pfizer Inc. (U.S.)
- 11.2.3. GlaxoSmithKline plc (U.K.)
- 11.2.4. Novartis AG (Switzerland)
- 11.2.5. Mylan N.V. (U.S.)
- 11.2.6. Teva Pharmaceutical Industries Ltd. (Israel)
- 11.2.7. Sanofi (France)
- 11.2.8. Boehringer Ingelheim International GmbH. (Germany)
- 11.2.9. AstraZeneca (U.K.)
- 11.2.10. Johnson & Johnson Private Limited (U.S.)
Chapter 12. Research Process
- 12.1. Research Process
- 12.1.1. Data Mining
- 12.1.2. Analysis
- 12.1.3. Market Estimation
- 12.1.4. Validation
- 12.1.5. Publishing
- 12.2. Research Attributes
- 12.3. Research Assumption